Posted by Joel Rothman
January 19th, 2010
Your’s truly is featured in a front page article in today’s National Law Journal by Jenna Greene entitled “Rule Reversal: Obama’s agencies after one year.” The article provides a look at six key regulatory areas since Obama took office.
On the topic of the FDA and regulation of dietary supplements, I am quoted as saying:
“The fear [...]
Posted by Hugo Ottolenghi
January 8th, 2010
Marketers of nutritional supplements often complain that they do not know what the FDA wants. Even after the agency sends a warning letter about misleading claims and advertising, its staff does not explain what would fall within the rules. That’s the reality; the FDA will tell you what’s wrong, not what’s right.
Through warning letters, the [...]
Posted by Joel Rothman
January 3rd, 2010
2009 was an incredible year for the dietary supplement industry. While the rest of American business floundered amidst the depths of a recession, the dietary supplement business thrived. Americans concerned about maintaining their good health stocked up on supplements by the shopping cartful.
In a year when initial public offerings and acquisitions were almost unheard of, [...]
Posted by Hugo Ottolenghi
December 24th, 2009
The rules are different here in the United States. Hyde Park Holistic Center in Cincinnati recently received a warning letter from the Food & Drug Administration that read like many others having to do with nutritional supplements and the H1N1 virus. In China, though, the same admonishment could not be heard.
First, the FDA’s message to [...]
Posted by Hugo Ottolenghi
December 13th, 2009
The first paragraph in the New York Times story said it all: “The Drug Enforcement Administration has classified as controlled substances three steroids that are marketed as dietary supplements, but an antidoping official warned that new steroids have taken their place on the shelves of nutrition stores.”
The DEA’s actions are the equivalent of the carnival [...]
Posted by Hugo Ottolenghi
November 16th, 2009
Two days of hearings before the FDA about search-based advertising for drugs produced one possible solution: fixed warnings for products. Google has proposed that its AdWords could include a hyperlinked line that warns consumers about the potential dangers of a drug.